New York – July 2018 – Tailwind Capital, a leading middle market private equity firm investing in growth-oriented companies in targeted sectors within healthcare, business services and industrial services, has completed the sale of Diamondback Drugs to Wedgewood Pharmacy, a New Jersey-based veterinary compounding pharmacy. Terms of the transaction were not disclosed.
Tailwind invested in Diamondback Drugs in November 2014. Since that time, Diamondback has driven significant growth through investing in the company’s infrastructure, expanding its sales and marketing resources and broadening its portfolio of products and solutions.
Fabian McCarthy, Tailwind Operating Executive and Diamondback CEO, commented, “We are thrilled with this outcome. Over the past four years, Tailwind and Diamondback have worked together successfully to drive growth and achieve significant milestones for the company.”
Geoff Raker, Partner at Tailwind, added, “We are very proud of what we have accomplished in partnership with Diamondback. The strategic combination of Diamondback and Wedgewood creates a leading provider within the veterinary compounding industry.”
About Diamondback Drugs
Diamondback Drugs is a veterinary compounding pharmacy that distributes pharmaceutical products to individual pet owners, veterinary offices and clinics. The company's compounding facility allows Diamondback to provide a broad veterinary compounded pharmaceutical offering, ranging from anti-infectives and ophthalmic preparations to cancer treatment solutions. Diamondback has grown from a small veterinary compounder into a growing platform serving pets in 50 states, as well as Canada and Mexico. For more information, please visit www.diamondbackdrugs.com.
About Tailwind Capital
Tailwind Capital is a leading middle market private equity firm focused on growth-oriented investments in targeted sectors within healthcare, business and industrial services. Tailwind partners with experienced management teams and entrepreneurs to transform businesses through organic growth initiatives, acquisitions, and operational and strategic improvements. Since inception, Tailwind has managed over $3 billion of committed equity capital, and has invested in 37 portfolio companies and 65 add-ons.